

Lesotho

Population 2015

2.1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.2 (0.63–1.9)	55 (29–89)
Mortality (HIV+TB only)	4.8 (3–7)	223 (139–328)
Incidence (includes HIV+TB)	17 (11–24)	788 (510–1 125)
Incidence (HIV+TB only)	12 (7.7–18)	566 (359–820)
Incidence (MDR/RR-TB)**	1.1 (0.76–1.5)	52 (36–70)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.54 (0.18–0.9)	5.9 (2.7–9.1)	6.5 (2.9–10)
Males	0.63 (0.36–0.9)	9.7 (6.8–13)	10 (7.2–14)
Total	1.2 (0.72–1.6)	16 (12–19)	17 (11–24)

TB case notifications, 2015

Total cases notified	7 892
Total new and relapse	7 594
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	96%
- % pulmonary	86%
- % bacteriologically confirmed among pulmonary	49%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	45% (32–70)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.37 (0.21–0.61)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	5 258	72%
- on antiretroviral therapy	4 152	79%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			430 (350–510)
Estimated % of TB cases with MDR/RR-TB	4.8% (3.7–5.9)	14% (9.3–18)	
% notified tested for rifampicin resistance	21%	57%	2 536
MDR/RR-TB cases tested for resistance to second-line drugs			8
Laboratory-confirmed cases		MDR/RR-TB: 332, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 217, XDR-TB: 5	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	70%	9 000
Previously treated cases, excluding relapse, registered in 2014	59%	936
HIV-positive TB cases, all types, registered in 2014	69%	5 466
MDR/RR-TB cases started on second-line treatment in 2013	63%	163
XDR-TB cases started on second-line treatment in 2013	33%	3

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	6.4
Funding source: 12% domestic, 19% international, 69% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)

